2015 HSC Section 1 Book of Articles

First page Previous page 254 Next page Last page

Kasabach-Merritt syndrome: a new in- dication for propranolol treatment. J Pediatr Hematol Oncol . 2011;33(4):e171 – e173 105. Litovitz TL, Schmitz BF, Matyunas N, Martin TG. 1987 annual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med . 1988;6(5):479 – 515 106. Love JN, Litovitz TL, Howell JM, Clancy C. Characterization of fatal beta blocker in- gestion: a review of the American Associ- ation of Poison Control Centers data from 1985 to 1995. J Toxicol Clin Toxicol . 1997;35 (4):353 – 359 107. Price CJ, Lattouf C, Baum B, et al. Pro- pranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospec- tive analysis. Arch Dermatol . 2011;147(12): 1371 – 1376 108. van Veen MR, van Hasselt PM, de Sain-van der Velden MG, et al. Metabolic pro fi les in children during fasting. Pediatrics . 2011; 127(4). Available at: www.pediatrics.org/ cgi/content/full/127/4/e1021

115. Solomon T, Ninnis J, Deming D, Merritt TA, Hopper A. Use of propranolol for treat- ment of hemangiomas in PHACE syn- drome. J Perinatol . 2011;31(11):739 – 741 116. Siegel D, Tefft K, Kelly T, et al. Stroke in children with posterior fossa brain mal- formations, hemangiomas, arterial anomalies, coarctation of the aorta and cardia defects, and eye abnormalities (PHACE) syndrome: a systematic review of the literature. Stroke . 2012;43(6):1672 – 1674 117. Webb AJ, Fischer U, Rothwell PM. Effects of b -blocker selectivity on blood pressure variability and stroke: a systematic re- view. Neurology . 2011;77(8):731 – 737 118. The fourth report on the diagnosis, eval- uation, and treatment of high blood pressure in children and adolescents. Pediatrics . 2004;114(suppl 2, 4th report): 555 – 576 119. Kent AL, Kecskes Z, Shadbolt B, Falk MC. Blood pressure in the fi rst year of life in healthy infants born at term. Pediatr Nephrol . 2007;22(10):1743 – 1749

109. Cavalli R, Buffon RB, de Souza M, Colli AM, Gelmetti C. Tumor lysis syndrome after propranolol therapy in ulcerative infantile hemangioma: rare complication or in- cidental fi nding? Dermatology . 2012;224 (2):106 – 109 110. Horton JN. Nominal group technique. A method of decision-making by committee. Anaesthesia . 1980;35(8):811 – 814 111. Michaëlsson M, Engle MA. Congenital complete heart block: an international study of the natural history. Cardiovasc Clin . 1972;4(3):85 – 101 112. Vetter VL, Rashkind WJ. Congenital com- plete heart block and connective-tissue disease. N Engl J Med . 1983;309(4):236 – 238 113. Bernstein DP, ed. History and Physical Evaluation . 18th ed. Philadelphia, PA: Saunders Elsevier; 2007 114. Frieden IJ, Reese V, Cohen D. PHACE syn- drome. The association of posterior fossa brain malformations, hemangiomas, ar- terial anomalies, coarctation of the aorta and cardiac defects, and eye abnormali- ties. Arch Dermatol . 1996;132(3):307 – 311

(Continued from fi rst page) Given the need for the multispecialty input, this was a highly collaborative process, and all authors have made substantial intellectual contributions to this article. Each author has met all three of the Pediatrics criteria. These authors drafted the initial manuscript (speci fi c section in parenthesis) and approved the fi nal manuscript as submitted. Drs Drolet (introduction), Frommelt (pretreatment evaluation), Chamlin (survey), Haggstrom (introduction), and Cassidy conceptualized and designed the consensus conference program and grant award from the National Institutes of Health that supported the consensus conference. These authors also contributed to the acquisition of data by participating in person in the consensus meeting in Chicago and the iterative decision-making process, as well as several conference calls following the meeting. They drafted the initial manuscript and approved the fi nal manuscript as submitted. Drs Frieden (conclusion), Boucek (adverse events), Bauman (proposed dosing regimen), Chiu (methods), Holland (hypoglycemia), Liberman (inpatient dose escalation), Ward (outpatient dose escalation), Metry (PHACE syndrome), and Puttgen (review of the hemangioma literature) contributed to the acquisition of data by participating in person in the consensus meeting and the iterative decision-making process, as well as several conference calls following the meeting. Drs Chun, Garzon, MacLellan-Tobert, Mancini, Seefeldt, Sidbury, Blei, Baselga, Darrow, Joachim, Kwon, Martin, Perkins, and Siegel contributed to the acquisition of data and analysis and interpretation of data by participating in person in the consensus meeting in Chicago and the iterative decision-making process, as well as several conference calls following the meeting. These authors all critically reviewed 11 drafts of this manuscript and approved the fi nal manuscript as submitted. www.pediatrics.org/cgi/doi/10.1542/peds.2012-1691 doi:10.1542/peds.2012-1691 Accepted for publication Aug 31, 2012 Address correspondence to Beth A. Drolet, MD, Dermatology Department, 8701 Watertown Plank Rd, TBRC, 2nd Floor, Suite C2010, Milwaukee, WI 53226. E-mail: bdrolet@mcw.edu

FINANCIAL DISCLOSURE: The following authors disclose a con fl ict of interest consisting of involvement in the HEMANGIOL study, which was sponsored by Pierre Fabre: Drs Mancini, Sidbury, and Baselga. Drs Frieden and Baselga also disclose that they acted as consultants for Pierre Fabre. The other authors have indicated they have no fi nancial relationships relevant to this article to disclose. FUNDING: This work was supported by grant NIH-NIAMS-1R34AR060881-01 from the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases. Funded by the National Institutes of Health (NIH).

DROLET et al

232

Made with FlippingBook